ALK and renal cell carcinoma: Similarly, ALK/ROS1 inhibitors (crizotinib, ceritinib) demonstrate efficacy in inflammatory myofibroblastic tumors (IMTs), NSCLC, and renal cell carcinomas (RCCs) harboring TPM3‐ALK/ROS1 fusions.